Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international nv - apalutamide - prostatiske neoplasmer - endokrine terapi - erleada er anført:i voksne mænd til behandling af ikke-metastatisk kastration resistent prostatakræft (nmcrpc), som er i høj risiko for at udvikle metastatisk sygdom. hos voksne mænd til behandling af metastatisk hormon-følsomme prostatakræft (mhspc) i kombination med androgen deprivation terapi (adt).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

eli lilly nederland b.v. - glucagon - diabetes mellitus - pancreas hormoner, hormoner glycogenolytic - baqsimi er indiceret til behandling af alvorlig hypoglykæmi hos voksne, unge og børn i alderen 4 år og derover med diabetes mellitus.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

tetris pharma b.v - glucagon - diabetes mellitus - pancreas hormoner, hormoner glycogenolytic - ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - abiraterone acetat - prostatiske neoplasmer - endokrine terapi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomyom - hypofysiske og hypotalamiske hormoner og analoger - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - køn hormoner og modulatorer af den genitale system, - oral contraceptive.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

krka, d.d., novo mesto - abiraterone acetat - prostatiske neoplasmer - endokrine terapi - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofysiske og hypotalamiske hormoner og analoger - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - relugolix - prostatiske neoplasmer - endokrine terapi - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostatiske neoplasmer - endokrine terapi - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.